Peer-Spectives
Oncololgy News Central
5.0
(1)
1 Listener
5.0
(1)
All episodes
Best episodes
Top 10 Peer-Spectives Episodes
Goodpods has curated a list of the 10 best Peer-Spectives episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to Peer-Spectives for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite Peer-Spectives episode by adding your comments to the episode page.
The HIMALAYA Study Presented at ASCO GI ’22: An Update on the State of Liver Cancer Treatment Today
Peer-Spectives
01/26/22 • 10 min
Ghassan Abou-Alfa, MD and Robert Figlin, MD, discuss the presentation of the HIMLAYA clinical study at ASCO GI ’22 and how this regimen may fit in the liver cancer treatment landscape
1 Listener
Bladder Cancer – Robert Figlin, MD, and Arjun Balar, MD, discuss clinical progress in bladder cancer
Peer-Spectives
02/28/21 • 11 min
Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Arjun Balar, MD, Director, Genitourinary Medical Oncology Program, NYU Langone's Perlmutter Cancer Center, discuss clinical progress in bladder cancer
New Standard of Care in Melanoma? Neoadjuvant Immunotherapy Offers "Fantastic" Potential, Expert Says
Peer-Spectives
06/13/24 • 25 min
From ASCO 2024
New Standard of Care in Melanoma? Neoadjuvant Immunotherapy Offers "Fantastic" Potential, Expert Says.
Dr. Robert Figlin speaks with Dr. Christian Blank from Leiden University
Multiple Myeloma – Sagar Lonial, MD, and Robert Figlin, MD, discuss clinical highlights from ASH 2018
Peer-Spectives
12/12/18 • 7 min
Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Sagar Lonial, MD, Professor and Chair, Hematology & Medical Oncology, Chief Medical Officer, Winship Cancer Institute of Emory University, discuss ALCYONE, GRIFFIN, and maintenance therapy (TOURMALINE-MM3), and other multiple myeloma clinical studies presented at the American Society of Hematology 2018 meeting
After CodeBreaK100:
Peer-Spectives
11/20/21 • 11 min
Kathryn Arbour, MD, joins host Robert Figlin, MD, to discuss the importance of the KRAS-targeted drug, sotorasib, in the treatment of non-small cell lung cancer.
Kathryn Arbour, MD, joins host Robert Figlin, MD, to discuss the role next-generation sequencing plays in lung cancer care, the responses seen with the KRAS-targeted drug, sotorasib, in CodeBreaK100, and what optimal use of the drug will look like down the road.
Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Edward Garon, MD, Director of Thoracic Oncology Program, Jonsson Comprehensive Cancer Center, Associate Professor of Medicine, David Geffen School of Medicine, UCLA, discuss promising agents in development for the management of NSCLC from ASCO20
06/26/24 • 13 min
From ASCO 2024
The time it takes for a novel cancer therapy to go from investigational new drug application to U.S. Food and Drug Administration (FDA) approval is typically longer than a decade. “There has to be a better way,” says Bob T. Li, MD, PhD, MPH, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York City and associate professor of medicine at Cornell University in Ithaca, New York.
Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Constantine Tam, MD, Haematologist and Disease Group Lead, Low Grade Lymphoma and Chronic Lymphocytic Leukemia, Peter MacCallum Cancer Centre, discuss the progress in Waldenstrom macroglobulinemia from ASCO20
Lung Cancer – Geoffrey Oxnard, MD, and Robert Figlin, MD, discuss integrating liquid biopsies into lung cancer care
Peer-Spectives
11/26/19 • 11 min
Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Geoffry R. Oxnard, MD, Associate Professor of Medicine, Associate Professor of Medicine, Dana Farber Cancer Instituate, Harvard Medical School, discuss integrating liquid biopsies into lung cancer care
07/05/24 • 11 min
The biggest data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in kidney cancer focused on biomarkers, says Brian I. Rini, MD, chief of clinical trials and the Ingram Professor of Cancer Research at the Vanderbilt-Ingram Cancer Center in Nashville. He discussed data from KEYNOTE-426 and several other key trials with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles.
Show more best episodes
Show more best episodes
FAQ
How many episodes does Peer-Spectives have?
Peer-Spectives currently has 123 episodes available.
What topics does Peer-Spectives cover?
The podcast is about Cancer, Medical, Podcasts, Education, Science, Oncology and Healthcare.
What is the most popular episode on Peer-Spectives?
The episode title 'The HIMALAYA Study Presented at ASCO GI ’22: An Update on the State of Liver Cancer Treatment Today' is the most popular.
What is the average episode length on Peer-Spectives?
The average episode length on Peer-Spectives is 12 minutes.
How often are episodes of Peer-Spectives released?
Episodes of Peer-Spectives are typically released every 12 days, 2 hours.
When was the first episode of Peer-Spectives?
The first episode of Peer-Spectives was released on Oct 3, 2018.
Show more FAQ
Show more FAQ